Inhibiting TAK1 in microglia has been shown to have therapeutic effects in experimental autoimmune encephalomyelitis (EAE) mice, an animal model widely used for immune studies in MS, by reducing the expression of inflammatory mediators and related chemokines (Goldmann et al., 2013). The gene discussed is MAP3K7; the disease is myeloid sarcoma.